Hughes and Associates

10/16/2026

Behind every breakthrough, there's probably a very good cup of coffee. 🍵

Because great science takes curiosity, collaboration, and sometimes... one more cup before the next big idea.

Here's to the people turning complex questions into meaningful discoveries!

10/13/2026

If your scientific team had a group chat name, what would it be? 🧪

“One More Question…”
“Connecting the Dots”
“What Does the Data Say?”

Behind those names are people who keep showing up, working through uncertainty, and helping each other move the science forward.

There’s the colleague who asks the question everyone overlooked. The person who turns a complicated result into a clear next step. The steady voice who helps the team regroup when a plan changes.

For hiring leaders, it’s a useful question: What contribution would make your team stronger right now?

Deep expertise? A fresh perspective? Someone who can connect disciplines and bring people along?

In our work with biopharma leaders, we’re reminded that hiring is an opportunity to strengthen how a team thinks, collaborates, and progresses.

This week, give a little recognition to the people who make the hard work feel possible.

And tell us: What would your team’s group chat be called?

10/07/2026

𝗔𝗖𝗼𝗣 𝟮𝟬𝟮𝟲 | 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗙𝗼𝗿𝘄𝗮𝗿𝗱 𝘁𝗼 𝘁𝗵𝗲 𝗖𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝗔𝗵𝗲𝗮𝗱

With ACoP 2026 approaching, we’re looking forward to learning from the Pharmacometrics community and catching up with colleagues.

The scientific sessions offer an opportunity to explore new approaches. Conversations between sessions add another perspective: how those approaches are being applied, what teams are learning, and which challenges they’re working through.

For those thinking about their team’s next steps, these exchanges can help clarify where deeper expertise or collaboration could support their programs.

Jay Chapman will be attending on behalf of Hughes & Associates and looks forward to reconnecting with familiar colleagues and meeting new ones.

If you’ll be at ACoP, we’d be happy to connect. We’re interested in hearing what you’re working on and what’s ahead for your team.

09/30/2026

What do biopharma layoffs mean for scientific teams in 2026?

Our latest review explores how workforce reductions can reshape specialized scientific work, as companies focus on fewer programs and shift responsibilities between internal teams and external partners. Headcount figures alone do not reveal which scientific capabilities are affected.

▶️ Watch the full conversation on our podcast page: https://www.haallc.com/podcast-page/

09/17/2026

When a biopharma company reduces its workforce, what happens to the scientific work that remains?

We looked at selected 2026 workforce announcements to understand what sits behind the headline numbers, from narrower pipelines and changing R&D priorities to shifts in how specialized scientific capabilities are supported.

Across Clinical Pharmacology, Pharmacometrics, DMPK, QSP, Bioanalysis, and related functions, the announcements offer a broader view of how scientific teams are evolving as companies adjust their portfolios and organizational structures.

See what we found in our latest blog: https://www.haallc.com/2026/09/17/biopharma-layoffs-2026-scientific-teams/

What do biopharma layoffs in 2026 mean for scientific teams? We examine how workforce changes are reshaping specialized R&D capabilities.

09/09/2026

Biopharma layoffs aren’t just a headcount story.

When pipeline priorities change, companies also have to rethink how they access specialized scientific capabilities.

Across Clinical Pharmacology, Pharmacometrics, DMPK, QSP and Bioanalysis, workforce decisions can affect which expertise stays internal, is shared across teams, or is accessed externally.

The bigger question isn't only “How many people were affected?”

It’s “Which capabilities does the organization still need, and how will it access them?”

That may tell us more about where biopharma is heading than the layoff numbers alone.

09/04/2026

What is changing in the Pharmacometrics talent market in 2026?

Our latest market analysis points to an expanding scope for experienced Pharmacometrics talent, with organizations looking beyond foundational quantitative expertise to broader strategic, regulatory, and modality-specific capabilities.

▶️ Watch the full conversation on our podcast page: https://www.haallc.com/podcast-page/

08/28/2026

What is the Pharmacometrics hiring market telling us in 2026? 📊

We took a closer look at the Pharmacometrics roles we’ve tracked in the first half of this year to see where demand is emerging, which capabilities are appearing most often, and how expectations are changing across different levels of the market.

See what these trends could mean for hiring.

Read the full blog: https://www.haallc.com/2026/08/28/pharmacometrics-talent-market-report-2026/

Discover the evolving Pharmacometrics Talent Market 2026 and the growing demand for skilled professionals in drug development.

08/26/2026

Across the Pharmacometrics roles we’ve been reviewing, one pattern has been particularly consistent.

Strong modeling expertise remains the foundation, but the scope often becomes considerably broader at more experienced levels.

Population PK/PD and exposure-response remain central. Beyond these foundations, we’re also seeing experience with model-based meta-analysis, disease progression modeling, time-to-event analysis, and clinical trial simulation, depending on the development question.

At the same time, more experienced roles frequently extend into dose optimization, regulatory strategy, and translating quantitative findings into broader development decisions.

It also highlights how varied experienced Pharmacometrics backgrounds can be across the market.

Two candidates may both have strong Pharmacometrics backgrounds, but the depth of their modeling experience, the questions they have applied it to, and their ability to connect those findings to development decisions can be quite different.

We’ve been taking a closer look at these patterns across the 2026 Pharmacometrics talent market.

More on what we’re seeing soon.

08/20/2026

Are remote scientific roles becoming harder to find in biopharma?

Remote opportunities haven’t disappeared. But across the Clinical Pharmacology positions we tracked, structured hybrid models are increasingly visible, with some employers requiring approximately 2–3 days onsite per week.

For Clinical Pharmacology professionals, geography is becoming relevant again, even in a discipline where much of the work can be performed remotely.

For employers, work-model requirements can directly impact the size and reach of the available talent pool.

👉 Swipe through to see what we’re seeing across onsite, hybrid, and remote Clinical Pharmacology hiring in 2026.